Evidence map›Paper›PMID 28894945›Full record

ArticlePlanta2018

A tabersonine 3-reductase Catharanthus roseus mutant accumulates vindoline pathway intermediates.

Alison Edge, Yang Qu, Michael L A E Easson, Antje M K Thamm, Kyung Hee Kim, Vincenzo De Luca

Abstract read
PubMed Publisher
In one paragraph

Article in Planta, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 3 countries.

Alison EdgeDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada.
Yang QuDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada.
Michael L A E EassonDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada.
Antje M K ThammDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada.
Kyung Hee KimDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada.
Vincenzo De LucaDepartment of Biological Sciences, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, L2S 3A1, Canada. vdeluca@brocku.ca.ORCID http://orcid.org/0000-0001-8925-9382
Brock University · CA

Funding

Canada Excellence Research Chairs, Government of Canada Tier 1 Canada Research Chair in Plant BiotechnologyNational Sciences and Engineering Research Council of Canada Discovery grant
6 · The paper itself

Abstract

MAIN

conclusionMonoterpenoid indole alkaloids (MIAs) have remarkable biological properties that have led to their medical uses for a variety of human diseases. Mutagenesis has been used to generate plants with new alkaloid profiles and a useful screen for rapid comparison of MIA profiles is described. The MIA mutants identified are useful for investigating MIA biosynthesis and for targeted production of these specialised metabolites. The Madagascar periwinkle (Catharanthus roseus) is the sole source of the dimeric anticancer monoterpenoid indole alkaloids (MIAs), 3',4'-anhydrovinblastine and derivatives, which are formed via the coupling of the MIAs, catharanthine and vindoline. While intense efforts to identify parts of the complex pathways involved in the assembly of these dimers have been successful, our understanding of MIA biochemistry in C. roseus remains limited. A simple thin layer chromatography screen of 4000 ethyl methanesulfonate-metagenized M2 plants is described to identify mutant lines with altered MIA profiles. One mutant (M2-1865) accumulated reduced levels of vindoline inside the leaves in favour of high levels of tabersonine-2,3-epoxide and 16-methoxytabersonine-2,3-epoxide on the leaf surface. This MIA profile suggested that changes in tabersonine 3-reductase (T3R) activity might be responsible for the observed phenotype. Molecular cloning of mutant and wild type T3R revealed two nucleotide substitutions at cytosine residues 565 (CAT to TAT) and 903 (ACC to ACA) in the mutant corresponding to substitution (H189Y) and silent (T305T) amino acid mutations, respectively, in the protein. The single amino acid substitution in the mutant T3R protein diminished the biochemical activity of T3R by 95% that explained the reason for the low vindoline phenotype of the mutant. This phenotype was recessive and exhibited standard Mendelian single-gene inheritance. The stable formation and accumulation of epoxides in the M2-1865 mutant provides a dependable biological source of these two MIAs.

Indexed as

Antineoplastic AgentsCatharanthusEpoxy CompoundsHumansIndole AlkaloidsMutationOxidoreductasesPhenotypePlant LeavesQuinolinesSecologanin Tryptamine AlkaloidsVinblastineVinca AlkaloidsAntineoplastic AgentscatharanthineEpoxy CompoundsIndole AlkaloidsOxidoreductasesQuinolinesSecologanin Tryptamine AlkaloidstabersonineVinblastineVinca Alkaloidsvindoline16-Methoxytabersonine-2,3-epoxideBiosynthesisEpoxidesMonoterpenoid indole alkaloidsMutantPathway suppressionTabersonine-2,3-epoxide

Identifiers

PMID28894945
OpenAlexW2754154917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.